Price movement over the last 24 hours
Alcon AG vs Nasdaq Inc — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Nasdaq Inc trades at $84.63 (market cap $48.88B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays the higher dividend (1.3%). Which is the better fit depends on your goals.
| ALC | NDAQ | |
|---|---|---|
Market Cap | $32.69B | $48.88B |
Sector | Health | Financials |
52-Week High | $92.22 | $100.98 |
52-Week Low | $62.02 | $76.85 |
Enterprise Value | $36.28B | $55.94B |
Dividend Yield | 0.54% | 1.3% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Nasdaq (NDAQ) trades at $86.43, up 2.09% with strong fundamental performance including 2025 revenue of $8.26B and net income of $1.79B. The stock shows bullish technical signals with support at $83 and resistance at $86, while maintaining consistent earnings beats in recent quarters. Recent news highlights Nasdaq's record trading volumes and strategic expansions.
Outlook remains positive with analyst consensus target of $103 (19% upside), though risks include market volatility sensitivity and competitive pressures. The company's dominant exchange position and growing IPO pipeline provide solid growth foundation for investors seeking financial services exposure.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →